179 results on '"Gribben, John G."'
Search Results
2. MD-1 downregulation is associated with reduced cell surface CD180 expression in CLL
3. B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities
4. Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).
5. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
6. NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma
7. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
8. Clinical Experience with CAR ‐T Cells for Treatment of B‐cell Lymphomas
9. PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma
10. A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma
11. CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach
12. PHGDH is required for germinal center formation and is a therapeutic target in MYC- driven lymphoma
13. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
14. CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny
15. S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
16. Targeting the methylome to improve CLL outcome
17. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
18. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA
19. Supplemental Information from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients
20. Supplemental Table from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients
21. Data from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients
22. Supplementary Figure S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
23. Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
24. Supplemental Figures from Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients
25. Supplementary Figure Legend from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
26. Lack of reproducibility of histopathological features in MYC ‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium
27. PI 3 Kinase, AKT , and m TOR Inhibitors
28. Pharmacologic Features of Drugs Targeting Bruton's Tyrosine Kinase (BTK)
29. Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1 -mutated myelodysplasia
30. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
31. A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care
32. Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma
33. Genomic profiling for clinical decision making in lymphoid neoplasms
34. Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation
35. Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
36. Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
37. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
38. A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)
39. Characterization of the Human Mesenchymal Stromal Compartment in Normal Homeostasis and Acute Myeloid Leukemia at the Level of the Single Cell
40. BRUIN CLL-314: A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
41. Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
42. EMT-like Activation in CLL Provides Novel Therapeutic Target
43. Mutational patterns along different evolution paths of follicular lymphoma
44. Genetic and phenotypic characterisation of HIV ‐associated aggressive B‐cell non‐Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
45. PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion
46. PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma
47. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
48. The role of BTK inhibitors on the tumor microenvironment in CLL
49. Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment
50. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.